References
- Begg, C., Cho, M., Eastwood, S., Horton, R., Moher, D., Olkin, I., Pitkin, R., Rennie, D., Schulz, K. F., Simal, D., & Stroup, D. F. (1996). Improving the quality of reporting of randomised controlled trials: the CONSORT statement. Journal of the American Medical Association, 276, 637— 639.
- Hayhurst, K. P., & Lewis, S. W. (2004). Patients' subjective rating of mental health improvement on clozapine. Schizophrenia Research, 67, 226.
- Hollis, S., & Campbell, F. (1999). What is meant by intention to treat analysis? Survey of published randomised controlled trials. British Medical Journal, 319, 670–674.
- Lewis, S., Davies, L., Jones, P., Barnes, T., Murray, R., Kerwin, R., Taylor, D., Hayhurst, K., Markwick, A., Lloyd, H., & Dunn, G. (2005). Randomised controlled trials of conventional antipsychotic versus new atypical drugs and new atypical drugs versus clozapine in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. HTA monograph, in press.
- Lloyd, H. M., Markwick, A. J., Page, E. R., Lewis, S., & Barnes, T. R. E. (2005). Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the CUtLASS study. International Journal of Psychiatry in Clinical Practice, 9, 35–40.
- Medical Research Council (2003). Clinical trials for tomorrow: An MRC review of randomised controlled trials. London: MRC.
- Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997). A comparison of clozapine and haloperidol in hospitalised patients with refractory schizophrenia. The New England Journal of Medicine, 337, 809–815.